Your browser doesn't support javascript.
loading
Identification of plasma metabolites associated with modifiable risk factors and endophenotypes reflecting Alzheimer's disease pathology.
Dong, Ruocheng; Denier-Fields, Diandra N; Van Hulle, Carol A; Kollmorgen, Gwendlyn; Suridjan, Ivonne; Wild, Norbert; Lu, Qiongshi; Anderson, Rozalyn M; Zetterberg, Henrik; Blennow, Kaj; Carlsson, Cynthia M; Johnson, Sterling C; Engelman, Corinne D.
Afiliação
  • Dong R; Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA.
  • Denier-Fields DN; Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA.
  • Van Hulle CA; Department of Nutrition Science, University of Wisconsin-Madison, Madison, WI, 53706, USA.
  • Kollmorgen G; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
  • Suridjan I; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
  • Wild N; Roche Diagnostics International Ltd, CH-6346, Rotkreuz, Switzerland.
  • Lu Q; Roche Diagnostics GmbH, 82377, Penzberg, Germany.
  • Anderson RM; Roche Diagnostics GmbH, 82377, Penzberg, Germany.
  • Zetterberg H; Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
  • Blennow K; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
  • Carlsson CM; Geriatric Research Education and Clinical Center, William. S. Middleton Memorial Veterans Hospital, Madison, WI, 53705, USA.
  • Johnson SC; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, S-43180, Mölndal, Sweden.
  • Engelman CD; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-43180, Mölndal, Sweden.
Eur J Epidemiol ; 38(5): 559-571, 2023 May.
Article em En | MEDLINE | ID: mdl-36964431
Modifiable factors can influence the risk for Alzheimer's disease (AD) and serve as targets for intervention; however, the biological mechanisms linking these factors to AD are unknown. This study aims to identify plasma metabolites associated with modifiable factors for AD, including MIND diet, physical activity, smoking, and caffeine intake, and test their association with AD endophenotypes to identify their potential roles in pathophysiological mechanisms. The association between each of the 757 plasma metabolites and four modifiable factors was tested in the wisconsin registry for Alzheimer's prevention cohort of initially cognitively unimpaired, asymptomatic middle-aged adults. After Bonferroni correction, the significant plasma metabolites were tested for association with each of the AD endophenotypes, including twelve cerebrospinal fluid (CSF) biomarkers, reflecting key pathophysiologies for AD, and four cognitive composite scores. Finally, causal mediation analyses were conducted to evaluate possible mediation effects. Analyses were performed using linear mixed-effects regression. A total of 27, 3, 23, and 24 metabolites were associated with MIND diet, physical activity, smoking, and caffeine intake, respectively. Potential mediation effects include beta-cryptoxanthin in the association between MIND diet and preclinical Alzheimer cognitive composite score, hippurate between MIND diet and immediate learning, glutamate between physical activity and CSF neurofilament light, and beta-cryptoxanthin between smoking and immediate learning. Our study identified several plasma metabolites that are associated with modifiable factors. These metabolites can be employed as biomarkers for tracking these factors, and they provide a potential biological pathway of how modifiable factors influence the human body and AD risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Endofenótipos / Doença de Alzheimer Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Endofenótipos / Doença de Alzheimer Idioma: En Ano de publicação: 2023 Tipo de documento: Article